The purpose of this study is to examine how brain imaging with amyloid PET help guide your doctors in how to treat patients with mild cognitive impairment (MCI) or dementia and whether these changes in treatment lead to better medical outcomes. The hypothesis is that amyloid PET will decrease uncertainty and increase confidence in the underlying cause of cognitive impairment, that this will translate into earlier counseling and interventions in these domains, and that these interventions will lead to improved outcomes.
Inclusion Criteria
- Medicare as primary insurance
- Diagnosis of mild cognitive impairment (MCI) or dementia
- Cause of cognitive impairment is uncertain
Exclusion Criteria
- Normal cognition or complaints not verified by cognitive testing
- Amyloid status already known based on prior imaging
- Hip/pelvic fracture within 12 months
Study Requirements
Participants will have an initial pre-PET clinic visit where medical history will be collected and the amyloid PET scan will be scheduled. They will then undergo the amyloid PET scan followed by a 90 day follow-up clinic visit to discuss the condition and management plans. Please allow for medical records and brain imaging to be collected for up to 3 years.
Number of research visits: 3
Length of participation: 3 years
